Many US biotechs lack ESG disclosure, finds study

Many US biotechs have ‘limited or no explicit ESG disclosure’ despite recognizing the growing importance of sustainability to investors and other stakeholders, according to new research by law firm Fenwick.

The study, which reviews 50 development-stage public companies with market caps between $1.3 bn and $4.6 bn, finds just 30 percent mention ESG issues – excluding references to diversity – in their public disclosures.

The amount and location of ESG information varies considerably, notes Fenwick. For example, 10 percent of the sample group produce a full sustainability report while others include only ‘brief statements in corporate governance documents regarding board or committee oversight of ESG’.

Fenwick defines ESG disclosure as where companies discuss ESG topics as a unified risk area or include specific terms like ‘ESG’ or ‘corporate sustainability’. The firm decided not to count mentions of diversity, given the large number of companies now reporting on this area.

Executive survey

While many biotechs have not yet embraced ESG disclosure, a separate survey by Fenwick suggests sustainability reporting is a growing priority for the sector. In a poll of more than 100 biotech executives, 74 percent say they expect their ESG disclosure to increase over the next year.

The survey also investigates which actions biotechs have taken in relation to ESG. The most common is to conduct a materiality assessment into risks and opportunities (selected by 42 percent), followed by tracking and/or collecting ESG data (36 percent) and the creation of an internal working group or committee (33 percent).

‘ESG activities vary with no single activity dominating, suggesting that many companies are at an early stage of implementation,’ write the report authors. ‘Similarly, companies that have not yet implemented ESG activities disclose a wide range of measures they intend to take, with tracking and/or collecting ESG information garnering the highest number of selections.’

Fenwick notes that biotechs seem to become more likely to report on ESG the longer they are public companies. ‘Given the number of recent IPOs in the biotech sector, we expect ESG disclosure will accelerate accordingly as these newly public companies mature and expand their governance and compliance functions,’ the report authors write.

Upcoming events

  • Briefing – Effective earnings preparation amid macro volatility
    Thursday, August 07, 2025

    Briefing – Effective earnings preparation amid macro volatility

    In partnership with WHEN 8.00 am PT / 11.00 am ET / 4.00 pm BST / 5.00 pm CET DURATION 45 minutes About the event Amid constant tariff news, geopolitical upheaval and other developments stemming from the new US administration, IR teams have their work cut out as they prepare…

    Online
  • Forum – AI & Technology
    Wednesday, November 12, 2025

    Forum – AI & Technology

    About the event As more investors and corporate communication teams embrace AI, machine learning and emerging technologies to inform their decision-making, investor relations professionals are facing a pivotal moment: adapt and lead, or risk falling behind. At this early but fast-moving stage of adoption, IR teams are asking important questions…

    New York, US
  • Forum & Awards – South East Asia
    Tuesday, December 02, 2025

    Forum & Awards – South East Asia

    Seizing opportunity in shifting markets For the past three decades, IR Impact has honored excellence in investor relations around the world and in 2025, we continue to recognize and help further IR best practice. We will be joined by senior IR professionals from across Indonesia, Malaysia, the Philippines, Singapore and Thailand for…

    Singapore

Explore

Andy White, Freelance WordPress Developer London